found in a smaller and more selected KRAS-positive stage IV NSCLC cohort (with only PD-L1 ≥50%, treated with first-line immunotherapy) an OS of 18.4 months versus 20.6 months for KRAS G12C (n = 86) versus non-G12C (n = 141), respectively. This evidence concerns the gene CD274 and non-small cell lung carcinoma.